Cancer Vaccines Market Size, Share, and Outlook, H2-2025 Report- By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Others), By Indication (Prostate Cancer, Bladder Cancer, Melanoma, Cervical Cancer, Others), By Technology (Recombinant Canc
Description
Cancer Vaccines Market Outlook
The global Cancer Vaccines Market Size is valued at $10.2 Billion in 2025 and is forecast to reach $15.1 Billion in 2032 at a CAGR of 5.8%.
The Cancer Vaccines Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Cancer Vaccines Market segments across 22 countries from 2021 to 2032. Key segments covered include By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Others), By Indication (Prostate Cancer, Bladder Cancer, Melanoma, Cervical Cancer, Others), By Technology (Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Cancer Vaccines Market Insights, 2025
In 2025, cancer vaccine development is moving from broad tumor-antigen approaches toward highly personalized, neoantigen-based platforms integrated with genomic profiling. mRNA-based cancer vaccines, propelled by manufacturing speed and flexibility proven in infectious disease, are now in multiple late-stage trials for melanoma, non-small cell lung cancer, and pancreatic cancer. Dendritic cell and peptide-based vaccines are being refined with optimized adjuvants to enhance T-cell priming, while combination regimens with checkpoint inhibitors are showing synergistic potential in early readouts. Hospitals participating in these trials are upgrading cold-chain logistics and GMP cell-processing suites to handle personalized batches. Regulatory bodies are emphasizing immune-monitoring endpoints alongside traditional progression-free survival to assess efficacy. Commercial-scale readiness is emerging through modular mRNA production facilities capable of rapid antigen design swaps, enabling adaptation to patient-specific tumor profiles within weeks.
Five Trends Shaping the Global Cancer Vaccines Market in 2025 and Beyond
The global Cancer Vaccines Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Cancer Vaccines Industry?
The Cancer Vaccines Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Cancer Vaccines Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Cancer Vaccines Market Segment Insights
The Cancer Vaccines Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Others), By Indication (Prostate Cancer, Bladder Cancer, Melanoma, Cervical Cancer, Others), By Technology (Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Cancer Vaccines Industry Value Chain
The chapter identifies potential companies and their operations across the global Cancer Vaccines Industry ecosystem. It assists decision-makers in evaluating global Cancer Vaccines Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Cancer Vaccines Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Cancer Vaccines Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Cancer Vaccines Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Cancer Vaccines Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Cancer Vaccines Market.
Europe Cancer Vaccines Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Cancer Vaccines Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Cancer Vaccines Industry competitiveness. The report analyses the key Cancer Vaccines Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Cancer Vaccines Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Cancer Vaccines Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Cancer Vaccines Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Cancer Vaccines Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Cancer Vaccines Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Cancer Vaccines Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Amgen Inc, AstraZeneca Plc, Bristol-Myers Squibb Co., Dendreon Pharmaceuticals LLC, Dynavax Technologies., Ferring B.V., GSK plc, Merck & Co. Inc, Moderna Inc, Sanofi. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Cancer Vaccines Market Scope
Leading Segments
By Type
Preventive Cancer Vaccines
Therapeutic Cancer Vaccines
Others
By Indication
Prostate Cancer
Bladder Cancer
Melanoma
Cervical Cancer
Others
By Technology
Recombinant Cancer Vaccines
Whole-cell Cancer Vaccines
Viral Vector and DNA Cancer Vaccines
Others
Leading Companies
Amgen Inc
AstraZeneca Plc
Bristol-Myers Squibb Co.
Dendreon Pharmaceuticals LLC
Dynavax Technologies.
Ferring B.V.
GSK plc
Merck & Co. Inc
Moderna Inc
Sanofi
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Cancer Vaccines Market Size is valued at $10.2 Billion in 2025 and is forecast to reach $15.1 Billion in 2032 at a CAGR of 5.8%.
The Cancer Vaccines Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Cancer Vaccines Market segments across 22 countries from 2021 to 2032. Key segments covered include By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Others), By Indication (Prostate Cancer, Bladder Cancer, Melanoma, Cervical Cancer, Others), By Technology (Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Cancer Vaccines Market Insights, 2025
In 2025, cancer vaccine development is moving from broad tumor-antigen approaches toward highly personalized, neoantigen-based platforms integrated with genomic profiling. mRNA-based cancer vaccines, propelled by manufacturing speed and flexibility proven in infectious disease, are now in multiple late-stage trials for melanoma, non-small cell lung cancer, and pancreatic cancer. Dendritic cell and peptide-based vaccines are being refined with optimized adjuvants to enhance T-cell priming, while combination regimens with checkpoint inhibitors are showing synergistic potential in early readouts. Hospitals participating in these trials are upgrading cold-chain logistics and GMP cell-processing suites to handle personalized batches. Regulatory bodies are emphasizing immune-monitoring endpoints alongside traditional progression-free survival to assess efficacy. Commercial-scale readiness is emerging through modular mRNA production facilities capable of rapid antigen design swaps, enabling adaptation to patient-specific tumor profiles within weeks.
Five Trends Shaping the Global Cancer Vaccines Market in 2025 and Beyond
The global Cancer Vaccines Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Cancer Vaccines Industry?
The Cancer Vaccines Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Cancer Vaccines Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Cancer Vaccines Market Segment Insights
The Cancer Vaccines Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Others), By Indication (Prostate Cancer, Bladder Cancer, Melanoma, Cervical Cancer, Others), By Technology (Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Cancer Vaccines Industry Value Chain
The chapter identifies potential companies and their operations across the global Cancer Vaccines Industry ecosystem. It assists decision-makers in evaluating global Cancer Vaccines Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Cancer Vaccines Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Cancer Vaccines Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Cancer Vaccines Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Cancer Vaccines Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Cancer Vaccines Market.
Europe Cancer Vaccines Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Cancer Vaccines Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Cancer Vaccines Industry competitiveness. The report analyses the key Cancer Vaccines Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Cancer Vaccines Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Cancer Vaccines Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Cancer Vaccines Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Cancer Vaccines Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Cancer Vaccines Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Cancer Vaccines Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Amgen Inc, AstraZeneca Plc, Bristol-Myers Squibb Co., Dendreon Pharmaceuticals LLC, Dynavax Technologies., Ferring B.V., GSK plc, Merck & Co. Inc, Moderna Inc, Sanofi. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Cancer Vaccines Market Scope
Leading Segments
By Type
Preventive Cancer Vaccines
Therapeutic Cancer Vaccines
Others
By Indication
Prostate Cancer
Bladder Cancer
Melanoma
Cervical Cancer
Others
By Technology
Recombinant Cancer Vaccines
Whole-cell Cancer Vaccines
Viral Vector and DNA Cancer Vaccines
Others
Leading Companies
Amgen Inc
AstraZeneca Plc
Bristol-Myers Squibb Co.
Dendreon Pharmaceuticals LLC
Dynavax Technologies.
Ferring B.V.
GSK plc
Merck & Co. Inc
Moderna Inc
Sanofi
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
199 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Cancer Vaccines Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Cancer Vaccines Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Cancer Vaccines Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Cancer Vaccines Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Cancer Vaccines Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Type
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
- Others
- By Indication
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Cervical Cancer
- Others
- By Technology
- Recombinant Cancer Vaccines
- Whole-cell Cancer Vaccines
- Viral Vector and DNA Cancer Vaccines
- Others
- 6. Global Cancer Vaccines Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Cancer Vaccines Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Cancer Vaccines Market Trends and Growth Opportunities
- 6.2.1 North America Cancer Vaccines Market Outlook by Type
- 6.2.2 North America Cancer Vaccines Market Outlook by Application
- 6.3 North America Cancer Vaccines Market Outlook by Country
- 6.3.1 The US Cancer Vaccines Market Outlook, 2021- 2032
- 6.3.2 Canada Cancer Vaccines Market Outlook, 2021- 2032
- 6.3.3 Mexico Cancer Vaccines Market Outlook, 2021- 2032
- 7. Europe Cancer Vaccines Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Cancer Vaccines Market Trends and Growth Opportunities
- 7.2.1 Europe Cancer Vaccines Market Outlook by Type
- 7.2.2 Europe Cancer Vaccines Market Outlook by Application
- 7.3 Europe Cancer Vaccines Market Outlook by Country
- 7.3.2 Germany Cancer Vaccines Market Outlook, 2021- 2032
- 7.3.3 France Cancer Vaccines Market Outlook, 2021- 2032
- 7.3.4 The UK Cancer Vaccines Market Outlook, 2021- 2032
- 7.3.5 Spain Cancer Vaccines Market Outlook, 2021- 2032
- 7.3.6 Italy Cancer Vaccines Market Outlook, 2021- 2032
- 7.3.7 Russia Cancer Vaccines Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Cancer Vaccines Market Outlook, 2021- 2032
- 8. Asia Pacific Cancer Vaccines Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Cancer Vaccines Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Cancer Vaccines Market Outlook by Type
- 8.2.2 Asia Pacific Cancer Vaccines Market Outlook by Application
- 8.3 Asia Pacific Cancer Vaccines Market Outlook by Country
- 8.3.1 China Cancer Vaccines Market Outlook, 2021- 2032
- 8.3.2 India Cancer Vaccines Market Outlook, 2021- 2032
- 8.3.3 Japan Cancer Vaccines Market Outlook, 2021- 2032
- 8.3.4 South Korea Cancer Vaccines Market Outlook, 2021- 2032
- 8.3.5 Australia Cancer Vaccines Market Outlook, 2021- 2032
- 8.3.6 South East Asia Cancer Vaccines Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Cancer Vaccines Market Outlook, 2021- 2032
- 9. South America Cancer Vaccines Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Cancer Vaccines Market Trends and Growth Opportunities
- 9.2.1 South America Cancer Vaccines Market Outlook by Type
- 9.2.2 South America Cancer Vaccines Market Outlook by Application
- 9.3 South America Cancer Vaccines Market Outlook by Country
- 9.3.1 Brazil Cancer Vaccines Market Outlook, 2021- 2032
- 9.3.2 Argentina Cancer Vaccines Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Cancer Vaccines Market Outlook, 2021- 2032
- 10. Middle East and Africa Cancer Vaccines Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Cancer Vaccines Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Cancer Vaccines Market Outlook by Type
- 10.2.2 Middle East and Africa Cancer Vaccines Market Outlook by Application
- 10.3 Middle East and Africa Cancer Vaccines Market Outlook by Country
- 10.3.1 Saudi Arabia Cancer Vaccines Market Outlook, 2021- 2032
- 10.3.2 The UAE Cancer Vaccines Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Cancer Vaccines Market Outlook, 2021- 2032
- 10.3.4 South Africa Cancer Vaccines Market Outlook, 2021- 2032
- 10.3.5 Egypt Cancer Vaccines Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Cancer Vaccines Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- Amgen Inc
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Dendreon Pharmaceuticals LLC
- Dynavax Technologies.
- Ferring B.V.
- GSK plc
- Merck & Co. Inc
- Moderna Inc
- Sanofi
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
